The present study has identified 4 cancer driver genes (PTCH1, DNMT3A, PTPRS, JAK2) that rank highest in responders and are linked to enhanced survival in the validation cohort, either as individual markers or as part of a grouped marker panel. Here, JAK2 is linked to cancer.